Adelaide Research & Scholarship: Search

Search

Results 31-40 of 90 (Search time: 0.003 seconds).

previous
1
2
3
4
5
6
7
...
9
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2006	Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: Back to the bench	Hui, C.; Hughes, T.
	2013	Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells	White, D.; Eadie, L.; Saunders, V.; Hiwase, D.; Hughes, T.
	2010	Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy	Hiwase, D.; White, D.; Zrim, S.; Saunders, V.; Vaz de Melo, J.; Hughes, T.
	2005	Dynamics of chronic myeloid leukaemia	Michor, F.; Hughes, T.; Iwasa, Y.; Branford, S.; Shah, N.; Sawyers, C.; Nowak, M.
	2013	NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis	Watkins, D.; Hughes, T.; White, D.; D'Andrea, R.
	2011	OCT-1 as a determinant of response to antileukemic treatment	Engler, J.; Hughes, T.; White, D.
	2013	Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation	Kok, C.; Watkins, D.; Leclercq, T.; D'Andrea, R.; Hughes, T.; White, D.
	2011	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial	Kantarjian, H.; Hochhaus, A.; Saglio, G.; de Souza, C.; Flinn, I.; Stenke, L.; Goh, Y.; Rosti, G.; Nakamae, H.; Gallagher, N.; Hoenekopp, A.; Blakesley, R.; Larson, R.; Hughes, T.
	2004	Monitoring of minimal residual disease in chronic myeloid leukemia	Faderl, S.; Hochhaus, A.; Hughes, T.
	2008	International standardisation of quantitative real-time RT-PCR for BCR-ABL	Cross, N.; Hughes, T.; Hochhaus, A.; Goldman, J.